Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dose Levels of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis
Conditions
Interventions
XP23829 400 mg QD
XP 23829 800 mg QD
+2 more
Locations
31
United States
XenoPort Investigational Site
Birmingham, Alabama, United States
XenoPort Investigational Site
Phoenix, Arizona, United States
XenoPort Investigational Site
Hot Springs, Arkansas, United States
XenoPort Investigational Site
Encinitas, California, United States
XenoPort Investigational Site
Fremont, California, United States
XenoPort Investigational Site
Fullerton, California, United States
Start Date
June 1, 2014
Primary Completion Date
May 1, 2015
Completion Date
August 1, 2015
Last Updated
April 12, 2022
NCT07474792
NCT06857942
NCT06979453
NCT07471048
NCT07449234
NCT07116967
Lead Sponsor
Dr. Reddy's Laboratories Limited
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions